These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19413736)

  • 1. Data safety monitoring boards: a word from a sponsor (NHLBI).
    Mondoro TH
    Transfusion; 2009 Aug; 49(8):1537-9. PubMed ID: 19413736
    [No Abstract]   [Full Text] [Related]  

  • 2. Data safety and monitoring boards for African clinical trials.
    Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NHLBI plans for the promise of cell-based therapies.
    Mondoro TH; Thomas JW; Henslee-Downey PJ; Peterson CM
    Cytotherapy; 2005; 7(4):317-27. PubMed ID: 16162453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 7. Assuring trial safety for children.
    Howie S; Mueller J; Whittle H
    Lancet; 2008 Jul; 372(9632):30. PubMed ID: 18603156
    [No Abstract]   [Full Text] [Related]  

  • 8. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.
    Tharmanathan P; Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRBs and monitoring the safety of clinical trials.
    Maloney DM
    Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095
    [No Abstract]   [Full Text] [Related]  

  • 11. NHLBI clinical trials workshop: an executive summary.
    Zheng G; Wu CO; Yang S; Waclawiw MA; DeMets DL; Geller NL
    Stat Med; 2012 Nov; 31(25):2938-43. PubMed ID: 22733431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research review boards dogged by criticism.
    Ledford H
    Nature; 2009 Apr; 458(7238):557. PubMed ID: 19340042
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current NHLBI perspectives on translational heart failure research.
    Lathrop DA; Skarlatos S
    J Mol Cell Cardiol; 2011 Oct; 51(4):441-3. PubMed ID: 20946899
    [No Abstract]   [Full Text] [Related]  

  • 16. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 17. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.